How does ACLX's PS Ratio compare to its peers?

ACLX is expensive based on its Price-To-Sales Ratio (30.3x) compared to the peer average (20x).

How does ACLX's PS Ratio compare vs other companies in the US Biotechs Industry?

ACLX is expensive based on its Price-To-Sales Ratio (30.3x) compared to the US Biotechs industry average (10.3x).

What is ACLX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACLX is expensive based on its Price-To-Sales Ratio (30.3x) compared to the estimated Fair Price-To-Sales Ratio (9.8x).

What is the Fair Price of ACLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ACLX ($87.22) is trading below our estimate of [[fair value]] ($207.44)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Arcellx (Nasdaq:ACLX) - Stock Price, News & Analysis

ACLX Stock Overview

Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. More details

ACLX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 58% below our estimate of its fair value

Revenue is forecast to grow 22.51% per year

Analysts in good agreement that stock price will rise by 28.2%

Risk Analysis

Earnings are forecast to decline by an average of 6.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Arcellx, Inc. Competitors

TG Therapeutics

NasdaqCM:TGTX

US$4.4b

Krystal Biotech

NasdaqGS:KRYS

US$5.1b

Ascendis Pharma

NasdaqGS:ASND

US$7.4b

SpringWorks Therapeutics

NasdaqGS:SWTX

US$2.8b

Price History & Performance

Summary of all time highs, changes and price drops for Arcellx
Historical stock prices
Current Share Price	US$87.22
52 Week High	US$107.37
52 Week Low	US$46.42
Beta	0.27
11 Month Change	-3.39%
3 Month Change	31.24%
1 Year Change	63.39%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	419.17%

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Oct 28

Recent updates

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Oct 28

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Sep 05

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Aug 10

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Jul 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Shareholder Returns

	ACLX	US Biotechs	US Market
7D	-12.9%	-6.5%	-1.0%
1Y	63.4%	14.6%	30.3%

Return vs Industry: ACLX exceeded the US Biotechs industry which returned 14.1% over the past year.

Return vs Market: ACLX exceeded the US Market which returned 30.4% over the past year.

Price Volatility

Is ACLX's price volatile compared to industry and market?
ACLX volatility
ACLX Average Weekly Movement	7.2%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ACLX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ACLX's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	130	Rami Elghandour	www.arcellx.com

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Arcellx, Inc. Fundamentals Summary

How do Arcellx's earnings and revenue compare to its market cap?
ACLX fundamental statistics
Market cap	US$4.74b
Earnings (TTM)	-US$40.42m
Revenue (TTM)	US$155.82m

30.3x

P/S Ratio

-116.7x

P/E Ratio

Is ACLX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACLX income statement (TTM)
Revenue	US$155.82m
Cost of Revenue	US$7.38m
Gross Profit	US$148.44m
Other Expenses	US$188.86m
Earnings	-US$40.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.75
Gross Margin	95.26%
Net Profit Margin	-25.94%
Debt/Equity Ratio	0%

How did ACLX perform over the long term?

See historical performance and comparison

ACLX Stock Overview

Rewards

Risk Analysis

Arcellx, Inc. Competitors

NasdaqCM:TGTX

US$4.4b

NasdaqGS:KRYS

US$5.1b

NasdaqGS:ASND

US$7.4b

NasdaqGS:SWTX

US$2.8b

Price History & Performance

Recent News & Updates

Consensus EPS estimates fall by 11%

Chief Financial Officer notifies of intention to sell stock

Price target increased by 9.7% to US$105

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Recent updates

Consensus EPS estimates fall by 11%

Chief Financial Officer notifies of intention to sell stock

Price target increased by 9.7% to US$105

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$89.67

Now 20% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock